An Analysis Of Mersana Therapeutics Inc. (MRSN) Stock

view original post

Mersana Therapeutics Inc. (NASDAQ:MRSN) has a beta value of 1.95 and has seen 1.5 million shares traded in the last trading session. The company, currently valued at $530.55M, closed the last trade at $5.49 per share which meant it gained $0.3 on the day or 5.78% during that session. The MRSN stock price is -169.58% off its 52-week high price of $14.80 and 51.18% above the 52-week low of $2.68. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.05 million shares traded. The 3-month trading volume is 1.29 million shares.

The consensus among analysts is that Mersana Therapeutics Inc. (MRSN) is a Buy stock at the moment, with a recommendation rating of 1.60. 0 analysts rate the stock as a Sell, while 1 rate it as Overweight. 1 out of 7 have rated it as a Hold, with 5 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -$0.55.

3 Tiny Stocks Primed to Explode The world’s greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We’ve set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Sporting 5.78% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on Tuesday, 07/19/22 when the MRSN stock price touched $5.49 or saw a rise of 5.51%. Year-to-date, Mersana Therapeutics Inc. shares have moved -11.74%, while the 5-day performance has seen it change 5.98%. Over the past 30 days, the shares of Mersana Therapeutics Inc. (NASDAQ:MRSN) have changed 74.29%. Short interest in the company has seen 4.28 million shares shorted with days to cover at 2.54.

Wall Street analysts have a consensus price target for the stock at $18.00, which means that the shares’ value could jump 69.5% from current levels. The projected low price target is $13.00 while the price target rests at a high of $26.00. In that case, then, we find that the current price level is -373.59% off the targeted high while a plunge would see the stock gain -136.79% from current levels.

Mersana Therapeutics Inc. (MRSN) estimates and forecasts

Figures show that Mersana Therapeutics Inc. shares have outperformed across the wider relevant industry. The company’s shares have lost -12.58% over the past 6 months, with this year growth rate of 11.62%, compared to 1.10% for the industry. Other than that, the company has, however, increased its growth outlook for the 2022 fiscal year revenue. Growth estimates for the current quarter are 6.80% and 11.10% for the next quarter. Revenue growth from the last financial year stood is estimated to be 27,783.70%.

7 analysts offering their estimates for the company have set an average revenue estimate of $1.61 million for the current quarter. 7 have an estimated revenue figure of $1.61 million for the next quarter concluding in Sep 2022. Year-ago sales stood $11k and $11k respectively for this quarter and the next, and analysts expect sales will grow by 14,536.40% for the current quarter and 14,536.40% for the next.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -31.80% over the past 5 years.

MRSN Dividends

Mersana Therapeutics Inc. is expected to release its next earnings report between February 24 and February 28 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.

Mersana Therapeutics Inc. (NASDAQ:MRSN)’s Major holders

Insiders own 1.13% of the company shares, while shares held by institutions stand at 85.31% with a share float percentage of 86.29%. Investors are also buoyed by the number of investors in a company, with Mersana Therapeutics Inc. having a total of 194 institutions that hold shares in the company. The top two institutional holders are Blackrock Inc. with over 7.63 million shares worth more than $30.43 million. As of Mar 30, 2022, Blackrock Inc. held 7.86% of shares outstanding.

The other major institutional holder is Avoro Capital Advisors LLC, with the holding of over 6.8 million shares as of Dec 30, 2021. The firm’s total holdings are worth over $42.3 million and represent 7.01% of shares outstanding.

Also the top two Mutual Funds that are holding company’s shares are SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund. As of Jan 30, 2022, the former fund manager holds about 3.36% shares in the company for having 3.26 million shares of worth $15.56 million while later fund manager owns 1.94 million shares of worth $12.04 million as of Dec 30, 2021, which makes it owner of about 2.00% of company’s outstanding stock.